This database contains 50 studies, archived under the term: "phenylcarbamates"
Click here to filter this large number of results.
Effect of cholinergic stimulation in early Alzheimer’s disease – functional imaging during a recognition memory task
Miettinen, Pekka S.,
Pihlajamäki, Maija,
Jauhiainen, Anne M.,
Tarkka, Ina M.,
Gröhn, Heidi,
Niskanen, Eini,
Hänninen, Tuomo,
Vanninen, Ritva,
Soininen, Hilkka
Treatment of Alzheimer’s disease (AD) with acetylcholinesterase inhibitors (AChEI) enhances cholinergic activity and alleviates clinical symptoms. In the present functional magnetic resonance imaging (fMRI) study, we investigated the effect of the AChEI rivastigmine on cognitive function and brain activation patterns during a face recognition memory task. Twenty patients with newly-diagnosed mild AD were administered a […]
Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer’s disease
Grossberg, G.,
Cummings, J.,
Frolich, L.,
Bellelli, G.,
Molinuevo, J. L.,
Krahnke, T.,
Strohmaier, C.
Background: Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer’s disease (AD).; Methods: Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24 h rivastigmine patch in patients with AD demonstrating functional and cognitive decline with […]
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer’s Disease: the MEMAGE study
Gareri, Pietro,
Putignano, Daria,
Castagna, Alberto,
Cotroneo, Antonino Maria,
De Palo, Grazia,
Fabbo, Andrea,
Forgione, Luigi,
Giacummo, Attilio,
Lacava, Roberto,
Marino, Saverio,
Simone, Maurizio,
Zurlo, Amedeo,
Putignano, Salvatore
Background: Combined therapy of memantine and acetylcholinesterase inhibitors (AChEIs) in patients with Alzheimer’s disease (AD) may be associated with higher benefits than either monotherapy.; Objective: This retrospective multicentric study conducted in seven Italian Ambulatory Centers for Dementia assessed the efficacy and safety of memantine 20 mg/day administered for 6 months in addition to an AChEI […]
Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study
Emre, Murat,
Poewe, Werner,
De Deyn, Peter Paul,
Barone, Paolo,
Kulisevsky, Jaime,
Pourcher, Emmanuelle,
van Laar, Teus,
Storch, Alexander,
Micheli, Federico,
Burn, David,
Durif, Frank,
Pahwa, Rajesh,
Callegari, Francesca,
Tenenbaum, Nadia,
Strohmaier, Christine
Objective: This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia.; Methods: This was a 76-week, prospective, open-label, randomized study in patients aged 50 to 85 years. Primary outcomes included incidence of, and discontinuation due to, predefined […]
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer’s disease: a multicenter, randomized, open-label, parallel-group study
Choi, Seong Hye,
Park, Kyung Won,
Na, Duk L.,
Han, Hyun Jeong,
Kim, Eun-Joo,
Shim, Yong S.,
Lee, Jae-Hong,
The EXPECT Study Group,
Objective: To compare the tolerability and efficacy of combination therapy of memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients with mild to moderate Alzheimer’s disease (AD).; Research Design and Methods: In this multicenter, randomized, open-label study, patients entered an 8-week run-in period (a 5 cm 2 rivastigmine patch for 4 weeks, then a […]
Diagnosis of Alzheimer’s disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire
Carcaillon, L.,
Berrut, G.,
Sellal, F.,
Dartigues, J. F.,
Gillette, S.,
Pere, J. J.,
Bourdeix, I.
Background: Patients with Alzheimer’s disease (AD) who deteriorate rapidly are likely to have a poorer prognosis. There is a clear need for a clinical assessment tool to detect such a decline in newly diagnosed patients.; Objective: To identify the predictive factors of rapid cognitive decline (RCD) in a cohort of patients with mild to moderate […]